Viatris Free Cash Flow 2010-2024 | VTRS
Viatris annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Viatris free cash flow for the quarter ending September 30, 2024 was 4,147.00, a year-over-year.
- Viatris free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.
- Viatris annual free cash flow for 2023 was $2.437B, a 4.84% decline from 2022.
- Viatris annual free cash flow for 2022 was $2.56B, a 0.68% decline from 2021.
- Viatris annual free cash flow for 2021 was $2.578B, a 160.17% increase from 2020.
| Viatris Annual Free Cash Flow | |
|---|---|
| 2023 | 2,436.60 |
| 2022 | 2,560.40 |
| 2021 | 2,578.00 |
| 2020 | 990.90 |
| 2019 | 1,618.50 |
| 2018 | 2,118.90 |
| 2017 | 1,875.60 |
| 2016 | 1,656.80 |
| 2015 | 1,645.60 |
| 2014 | 689.50 |
| 2013 | 797.30 |
| 2012 | 660.00 |
| 2011 | 440.58 |
| 2010 | 743.56 |
| 2009 | 450.67 |
| Viatris Quarterly Free Cash Flow | |
|---|---|
| 2024-09-30 | 4,147.00 |
| 2024-06-30 | 1,564.20 |
| 2024-03-31 | 806.10 |
| 2023-12-31 | 2,436.60 |
| 2023-09-30 | 2,181.40 |
| 2023-06-30 | 1,393.80 |
| 2023-03-31 | 924.10 |
| 2022-12-31 | 2,560.40 |
| 2022-09-30 | 2,571.10 |
| 2022-06-30 | 1,805.40 |
| 2022-03-31 | 1,079.10 |
| 2021-12-31 | 2,578.00 |
| 2021-09-30 | 2,250.10 |
| 2021-06-30 | 1,284.90 |
| 2021-03-31 | 811.80 |
| 2020-12-31 | 990.90 |
| 2020-09-30 | 1,071.60 |
| 2020-06-30 | 584.00 |
| 2020-03-31 | 248.10 |
| 2019-12-31 | 1,618.50 |
| 2019-09-30 | 1,001.70 |
| 2019-06-30 | 532.00 |
| 2019-03-31 | -92.60 |
| 2018-12-31 | 2,118.90 |
| 2018-09-30 | 1,568.20 |
| 2018-06-30 | 976.10 |
| 2018-03-31 | 591.10 |
| 2017-12-31 | 1,875.60 |
| 2017-09-30 | 1,444.00 |
| 2017-06-30 | 942.50 |
| 2017-03-31 | 425.60 |
| 2016-12-31 | 1,656.80 |
| 2016-09-30 | 1,458.20 |
| 2016-06-30 | 376.10 |
| 2016-03-31 | 28.70 |
| 2015-12-31 | 1,645.60 |
| 2015-09-30 | 1,149.20 |
| 2015-06-30 | 259.70 |
| 2015-03-31 | 218.90 |
| 2014-12-31 | 689.50 |
| 2014-09-30 | 676.70 |
| 2014-06-30 | 299.20 |
| 2014-03-31 | 195.80 |
| 2013-12-31 | 797.30 |
| 2013-09-30 | 450.20 |
| 2013-06-30 | 148.30 |
| 2013-03-31 | 34.50 |
| 2012-12-31 | 660.00 |
| 2012-09-30 | 514.38 |
| 2012-06-30 | 96.68 |
| 2012-03-31 | -142.82 |
| 2011-12-31 | 440.58 |
| 2011-09-30 | 260.26 |
| 2011-06-30 | 31.93 |
| 2011-03-31 | -86.92 |
| 2010-12-31 | 743.56 |
| 2010-09-30 | 645.63 |
| 2010-06-30 | 305.84 |
| 2010-03-31 | 220.52 |
| 2009-12-31 | 450.67 |
| 2009-09-30 | 463.42 |
| 2009-06-30 | 283.21 |
| 2009-03-31 | 95.23 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $14.478B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $84.995B | 10.55 |
| Cencora (COR) | United States | $43.734B | 16.44 |
| DiDi Global (DIDIY) | China | $22.941B | 0.00 |
| Natera (NTRA) | United States | $20.871B | 0.00 |
| ICON (ICLR) | Ireland | $16.879B | 15.03 |
| Avantor (AVTR) | United States | $14.307B | 21.45 |
| Revvity (RVTY) | United States | $13.453B | 23.37 |
| BioMerieux (BMXMF) | France | $12.659B | 0.00 |
| CochLear (CHEOY) | Australia | $11.807B | 0.00 |
| Solventum (SOLV) | United States | $11.540B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.417B | 29.35 |
| Doximity (DOCS) | United States | $10.302B | 60.64 |
| Charles River Laboratories (CRL) | United States | $9.314B | 18.00 |
| HealthEquity (HQY) | United States | $8.212B | 41.20 |
| Sonic Healthcare (SKHHY) | Australia | $8.208B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.322B | 29.43 |
| Amplifon S.p.A (AMFPF) | Italy | $5.864B | 29.89 |
| Sotera Health (SHC) | United States | $3.759B | 20.11 |
| Organon (OGN) | United States | $3.719B | 3.75 |
| BrightSpring Health Services (BTSG) | United States | $2.967B | 63.11 |
| Surgery Partners (SGRY) | United States | $2.493B | 28.42 |
| Concentras Parent (CON) | United States | $2.491B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.291B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.069B | 0.00 |
| Premier (PINC) | United States | $2.067B | 10.76 |
| PACS (PACS) | United States | $1.992B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.969B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.730B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.711B | 44.90 |
| Teladoc Health (TDOC) | United States | $1.544B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.224B | 11.98 |
| Progyny (PGNY) | United States | $1.208B | 24.47 |
| Embecta (EMBC) | United States | $1.161B | 8.12 |
| CareDx (CDNA) | United States | $1.102B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.090B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.874B | 5.91 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Agilon Health (AGL) | United States | $0.775B | 0.00 |
| SBC Medicals (SBC) | United States | $0.649B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.492B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.478B | 0.00 |
| DocGo (DCGO) | United States | $0.444B | 16.73 |
| Sonida Senior Living (SNDA) | United States | $0.441B | 0.00 |
| Enhabit (EHAB) | United States | $0.387B | 33.48 |
| Sera Prognostics (SERA) | United States | $0.275B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.268B | 0.00 |
| LifeMD (LFMD) | United States | $0.212B | 0.00 |
| Biodesix (BDSX) | United States | $0.198B | 0.00 |
| Beauty Health (SKIN) | United States | $0.176B | 0.00 |
| Nutex Health (NUTX) | United States | $0.160B | 0.00 |
| ModivCare (MODV) | United States | $0.156B | 8.44 |
| MultiPlan (MPLN) | United States | $0.108B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.099B | 0.00 |
| So-Young (SY) | China | $0.093B | 15.69 |
| IceCure Medical (ICCM) | Israel | $0.052B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| OncoCyte (OCX) | United States | $0.037B | 0.00 |
| NeueHealth (NEUE) | United States | $0.033B | 0.87 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.023B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.023B | 0.00 |
| Oncology Institute (TOI) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| KindlyMD (KDLY) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |